Mustafa Tariq Khan

Dr. Mustafa Tariq Khan


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MKMustafa Tariq Khan
Mustafa Tariq Khan
RAReem Al-dhaleai
Reem Al-dhaleai
SASarah M. Alayadhi
Sarah M. Alayadhi
ZAZainab Alhalwachi
Zainab Alhalwachi
ABAlexandra E. Butler
Alexandra E. Butler
Gene therapy and RNA (ribonucleic acid)-based therapeutic strategies have emerged as promising alternatives to conventional diabetes treatments, significantly expanding the therapeutic landscape using viral and non-viral vectors, and RNA modalities such as mRNA (messenger ribonucleic acid), siRNA (small interfering ribonucleic acid) and miRNA (micro ribonucleic acid). Recent advancements in these fields have led to notable preclinical successes and ongoing clinical trials, yet they are accompanied by debates over safety, efficacy and ethical considerations that underscore the complexity of clinical translation. This review offers a comprehensive analysis of the underlying mechanisms by which these treatments target diabetes, critically evaluating the fundamental concepts and mechanistic insights that form their basis, while highlighting current research gaps, such as the challenges in long-term stability and efficient delivery of RNA-based therapies, and potential adverse effects associated with gene therapy techniques. By synthesizing diverse perspectives and controversies, the review outlines future directions and interdisciplinary approaches aimed at overcoming existing hurdles, ultimately setting the stage for innovative, personalized diabetes management and addressing the broader clinical and regulatory implications of these emerging therapeutic strategies.

10 September 2026 in Biosensors
Verified
Journal Article
Open access
PDF file
RAReem Al-dhaleai
Reem Al-dhaleai
MKMustafa Tariq Khan
Mustafa Tariq Khan
ZCZaid Chilmeran
Zaid Chilmeran
AAAbdulrahman Alsadeq
Abdulrahman Alsadeq
ABAlexandra E. Butler
Alexandra E. Butler
Closed-loop insulin delivery, or the artificial pancreas, has evolved from an ambitious engineering concept into one of the most consequential advances in diabetes technology. By integrating continuous glucose monitoring, insulin pumps, and control algorithms into a single feedback system, these platforms aim to shift diabetes care from repeated manual correction toward more anticipatory and adaptive glucose regulation. The field has progressed from early proof-of-concept systems to contemporary hybrid closed-loop platforms, reflecting a deeper shift in diabetes management itself: from treating glucose excursions after they occur to trying to blunt them in real time. Its clinical relevance is greatest in type 1 diabetes, where the burden of self-management is high and the consequences of glycemic instability are immediate. This review introduces the major technologies and evidence shaping the field, with emphasis on the control strategies that drive system behavior, and asks which currently available closed-loop systems offer the best balance of glycemic benefit, usability, and translational readiness for routine diabetes care. Across randomized trials and real-world studies, automated insulin delivery has consistently improved time in range, reduced hypoglycemia, and enhanced patient experience, particularly in pediatric populations. At the same time, important limitations remain: sensor lag, the physiologic constraints of subcutaneous insulin, device complexity, cost, and unequal access limit full autonomy and widespread adoption. Looking ahead, the next phase of progress will likely depend on more adaptive artificial intelligence, improved meal detection, multimodal wearable data, and multi-hormone systems that move the field closer to truly physiologic glucose control.